“Metformin and SGLT2-I Therapy Reduces Risks in Type 2 Diabetes and Cirrhosis Patients, Except MASH-Related Cirrhosis”

https://pubmed.ncbi.nlm.nih.gov/38114915

In patients with type 2 diabetes and cirrhosis, dual metformin and SGLT2-I therapy is associated with reduced risk of mortality, hepatic decompensation, and hepatocellular carcinoma, except in those with cirrhosis due to MASH.